




PHARMACEUTICAL 2021

MANNKIND CORP
Rank 353 of 402

mannkind





PHARMACEUTICAL 2021

MANNKIND CORP
Rank 353 of 402

mannkind

The relative strengths and weaknesses of MANNKIND CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MANNKIND CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 32% points. The greatest weakness of MANNKIND CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 142% points.

The company's Economic Capital Ratio, given in the ranking table, is -185%, being 232% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	79,476
Cost of Goods Sold	15,084
Intangible Assets	0
Liabilities, Current	73,705
Liabilities, Non-Current	2,864
Other Assets	3,265
Other Compr. Net Income	-19
Other Expenses	32,467
Other Liabilities	212,458
Other Net Income	-9,545
Other Revenues	65,144
Property and Equipment	25,867
Research and Development	6,248
Selling, General and Administrative Expense	59,040

Output Variable	Value in 1000 USD
Assets	108,608
Liabilities	289,027
Expenses	112,839
Revenues	65,144
Stockholders Equity	-180,419
Net Income	-57,240
Comprehensive Net Income	-57,250
Economic Capital Ratio	-185%